Kathmere Capital Management LLC Takes Position in GSK PLC Sponsored ADR (NYSE:GSK)

Kathmere Capital Management LLC purchased a new stake in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) in the first quarter, according to its most recent disclosure with the SEC. The firm purchased 7,463 shares of the pharmaceutical company's stock, valued at approximately $289,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in GSK. Olde Wealth Management LLC purchased a new position in GSK in the 1st quarter valued at about $36,000. Lee Danner & Bass Inc. acquired a new stake in GSK during the 4th quarter valued at approximately $39,000. First Pacific Financial purchased a new stake in GSK during the 1st quarter worth approximately $45,000. CX Institutional acquired a new position in shares of GSK in the 1st quarter valued at approximately $46,000. Finally, HM Payson & Co. boosted its stake in shares of GSK by 79.7% during the 1st quarter. HM Payson & Co. now owns 1,308 shares of the pharmaceutical company's stock valued at $51,000 after buying an additional 580 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on GSK. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a research note on Monday, April 28th. Wall Street Zen downgraded shares of GSK from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Finally, BNP Paribas started coverage on GSK in a report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price objective for the company. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $37.38.

GSK Stock Performance

GSK stock traded up $0.06 during trading on Monday, hitting $38.34. 4,797,454 shares of the company's stock traded hands, compared to its average volume of 5,208,889. The stock has a fifty day moving average price of $38.98 and a two-hundred day moving average price of $37.30. The company has a quick ratio of 0.58, a current ratio of 0.87 and a debt-to-equity ratio of 1.21. GSK PLC Sponsored ADR has a 52 week low of $31.72 and a 52 week high of $44.67. The stock has a market capitalization of $78.49 billion, a price-to-earnings ratio of 19.76, a price-to-earnings-growth ratio of 1.54 and a beta of 0.50.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, beating analysts' consensus estimates of $1.08 by $0.05. GSK had a net margin of 9.89% and a return on equity of 48.82%. The business had revenue of $10.06 billion during the quarter, compared to the consensus estimate of $7.52 billion. During the same quarter in the prior year, the firm earned $0.43 EPS. The company's revenue for the quarter was up 2.1% compared to the same quarter last year. As a group, equities analysts anticipate that GSK PLC Sponsored ADR will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, July 10th. Investors of record on Friday, May 16th were issued a $0.4216 dividend. This is an increase from GSK's previous quarterly dividend of $0.39. The ex-dividend date was Friday, May 16th. This represents a $1.69 annualized dividend and a dividend yield of 4.40%. GSK's dividend payout ratio (DPR) is 88.14%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.